Literature DB >> 1322953

Induction and inhibition of bovine leukaemia virus expression in naturally infected cells.

R O Zandomeni1, M Carrera-Zandomeni, E Esteban, W Donawick, J F Ferrer.   

Abstract

Bovine leukaemia virus (BLV) resides in infected lymphocytes in a latent, repressed state but becomes expressed a few hours after the cells are cultured in vitro. We have identified several conditions and factors affecting the expression of BLV in short-term cultures of naturally infected lymphoid cells. The presence of foetal calf serum in the culture medium greatly stimulates virus expression. This stimulation is not due to cellular proliferation. Transcription of BLV RNA and synthesis of p25 in the cultures of peripheral blood lymphocytes are preceded by a lag period of several hours. Synthesis of BLV p25 in these cultures takes place almost immediately after viral RNA synthesis. Extending previous results, we demonstrate that the plasma and lymphatic fluid of cattle contain factors that suppress and stimulate BLV expression. As a result of systematic examination of several parameters, we have developed reproducible assays for the detection of these factors. It is very likely that their relative concentration in the host is an important determinant of susceptibility and resistance to the development of lymphosarcoma and persistent lymphocytosis in BLV-infected cattle.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1322953     DOI: 10.1099/0022-1317-73-8-1915

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  9 in total

Review 1.  Lymphoid leukosis viruses, their recognition as 'persistent' viruses and comparisons with certain other retroviruses of veterinary importance.

Authors:  C Darcel
Journal:  Vet Res Commun       Date:  1996       Impact factor: 2.459

2.  Isolation of a bovine plasma fibronectin-containing complex which inhibits the expression of bovine leukemia virus p24.

Authors:  Marianne J van den Heuvel; Barbara J Jefferson; Robert M Jacobs
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

3.  cis-Acting inhibitory elements within the pol-env region of human T-cell leukemia virus type 1 possibly involved in viral persistence.

Authors:  A Saiga; S Orita; N Minoura-Tada; M Maeda; Y Aono; M Asakawa; K Nakahara; R Kubota; M Osame; H Igarashi
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

4.  Antiviral activity of shiga toxin 1: suppression of bovine leukemia virus-related spontaneous lymphocyte proliferation.

Authors:  W A Ferens; C J Hovde
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

5.  Mapping of B-neutralizing and T-helper cell epitopes on the bovine leukemia virus external glycoprotein gp51.

Authors:  I Callebaut; V Vonèche; A Mager; O Fumière; V Krchnak; M Merza; J Zavada; M Mammerickx; A Burny; D Portetelle
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

6.  Defibrinated bovine plasma inhibits retroviral transcription by blocking p52 activation of the NFkappaB element in the long terminal repeat.

Authors:  Marianne J van den Heuvel; Karen F Copeland; Elizabeth C Cates; Barbara J Jefferson; Robert M Jacobs
Journal:  Can J Vet Res       Date:  2007-04       Impact factor: 1.310

7.  In vivo protein binding and functional analysis of cis-acting elements in the U3 region of the bovine leukemia virus long terminal repeat.

Authors:  J Xiao; G C Buehring
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

8.  The CREB, ATF-1, and ATF-2 transcription factors from bovine leukemia virus-infected B lymphocytes activate viral expression.

Authors:  E Adam; P Kerkhofs; M Mammerickx; A Burny; R Kettmann; L Willems
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

9.  Fetal calf serum inhibits virus genome expression in Madin-Darby canine kidney cells persistently infected with influenza A virus.

Authors:  Md Jaber Hossain; Isamu Mori; Li Dong; Beixing Liu; Yoshinobu Kimura
Journal:  Med Microbiol Immunol       Date:  2007-07-05       Impact factor: 3.402

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.